Literature DB >> 9579168

Advances in haemolytic uraemic syndrome.

C M Taylor1, L A Monnens.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9579168      PMCID： PMC1717470          DOI： 10.1136/adc.78.2.190

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


× No keyword cloud information.
  24 in total

1.  Verocytotoxin-1 induces apoptosis in vero cells.

Authors:  C D Inward; J Williams; I Chant; J Crocker; D V Milford; P E Rose; C M Taylor
Journal:  J Infect       Date:  1995-05       Impact factor: 6.072

2.  Signal transduction responses following adhesion of verocytotoxin-producing Escherichia coli.

Authors:  A Ismaili; D J Philpott; M T Dytoc; P M Sherman
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

3.  Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: implications for the pathogenesis of the hemolytic uremic syndrome.

Authors:  N C van de Kar; L A Monnens; M A Karmali; V W van Hinsbergh
Journal:  Blood       Date:  1992-12-01       Impact factor: 22.113

4.  Prognostic markers in diarrhoea-associated haemolytic-uraemic syndrome: initial neutrophil count, human neutrophil elastase and von Willebrand factor antigen.

Authors:  D V Milford; J Staten; I MacGreggor; J Dawes; C M Taylor; F G Hill
Journal:  Nephrol Dial Transplant       Date:  1991       Impact factor: 5.992

5.  Plasma cytokine levels in hemolytic uremic syndrome.

Authors:  N C van de Kar; R W Sauerwein; P N Demacker; G E Grau; V W van Hinsbergh; L A Monnens
Journal:  Nephron       Date:  1995       Impact factor: 2.847

6.  Neutrophil activation in the haemolytic uraemic syndrome: free and complexed elastase in plasma.

Authors:  M M Fitzpatrick; V Shah; G Filler; M J Dillon; T M Barratt
Journal:  Pediatr Nephrol       Date:  1992-01       Impact factor: 3.714

7.  Endothelial heterogeneity in Shiga toxin receptors and responses.

Authors:  T G Obrig; C B Louise; C A Lingwood; B Boyd; L Barley-Maloney; T O Daniel
Journal:  J Biol Chem       Date:  1993-07-25       Impact factor: 5.157

8.  Interleukin-8 and polymorphoneutrophil leucocyte activation in hemolytic uremic syndrome of childhood.

Authors:  M M Fitzpatrick; V Shah; R S Trompeter; M J Dillon; T M Barratt
Journal:  Kidney Int       Date:  1992-10       Impact factor: 10.612

9.  Reproduction of edema disease of swine with purified Shiga-like toxin-II variant.

Authors:  D L MacLeod; C L Gyles; B P Wilcock
Journal:  Vet Pathol       Date:  1991-01       Impact factor: 2.221

10.  Shiga-like toxin II-related cytotoxins in Citrobacter freundii strains from humans and beef samples.

Authors:  H Schmidt; M Montag; J Bockemühl; J Heesemann; H Karch
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441
View more
  4 in total

1.  Haemolytic uraemic syndrome and E coli O157.

Authors:  M Fitzpatrick
Journal:  BMJ       Date:  1999-03-13

Review 2.  Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence.

Authors:  Werner Keenswijk; Ann Raes; Johan Vande Walle
Journal:  Eur J Pediatr       Date:  2017-12-29       Impact factor: 3.183

Review 3.  Haemolytic uraemic syndrome.

Authors:  W L Robson
Journal:  Paediatr Drugs       Date:  2000 Jul-Aug       Impact factor: 3.022

Review 4.  Infection by Shiga toxin-producing Escherichia coli: an overview.

Authors:  Mohamed A Karmali
Journal:  Mol Biotechnol       Date:  2004-02       Impact factor: 2.695
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.